Evaluation of [(89)Zr]Trastuzumab-PET/CT in Differentiating HER2-Positive from HER2-Negative Breast Cancer

PURPOSE: To evaluate whether tumor uptake of [(89)Zr]trastuzumab can distinguish HER2-positive from HER2-negative breast cancer. METHODS: Women with HER2-positive (n=34) and HER2-negative (n=16) breast cancer underwent PET/CT 5 ± 2 days following [(89)Zr]trastuzumab administration. HER2 status was d...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Breast Cancer Res Treat
Päätekijät: Dehdashti, Farrokh, Wu, Ningying, Bose, Ron, Naughton, Michael J., Ma, Cynthia X., Marquez-Nostra, Bernadette V., Diebolder, Philipp, Mpoy, Cedric, Rogers, Buck E., Lapi, Suzanne E., Laforest, Richard, Siegel, Barry A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955803/
https://ncbi.nlm.nih.gov/pubmed/29442264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4696-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia